Development of Management Algorithm for Non-Metastatic Muscle-Invasive Urothelial Cancer: A Short Communication by the Hellenic Genito-Urinary Cancer Group (HGUCG)
John Dimitriadis and Aristotle Bamias*
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
- *Corresponding Author:
- Aristotle Bamias
Department of Clinical Therapeutics
National and Kapodistrian University of Athens
Tel: +30 2103381845
E-mail: [email protected]
Received date: April 20, 2017; Accepted date: July 05, 2017; Published date: July 13, 2017
Citation: Dimitriadis J, Bamias A (2017) Development of Management Algorithm for Non-Metastatic Muscle-Invasive Urothelial Cancer: A Short Communication by the Hellenic Genito-Urinary Cancer Group (HGUCG). Chemo Open Access 6:239. doi:10.4172/2167-7700.1000239
Copyright: © 2017 Dimitriadis J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Urothelial cancer (UC) may develop anywhere along the urinary tract (kidney, ureter, bladder, urethra). It is characterized as nonmuscle invasive, muscle invasive and metastatic, and these categories differ in prognosis and management. Non-metastatic UC is an ideal example for multidisciplinary management, since its treatment requires participation of urologists, pathologists, medical oncologists and radiation oncologists. Therefore, constant efforts of different medical societies to compose clinical practice guidelines (CPGs) on the management of non-metastatic muscle invasive UC (nmMIUC) have taken place [1-12]. The main issue is that most of these guidelines are based on different levels of evidence (LoE) producing different grades of recommendation (GoR) and, along with the lack of large randomised clinical trials, makes their implementation on everyday clinical practice problematic in certain aspects.